Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GQ1001 in HER2-positive advanced solid tumors
NCT04450732Phase 1Recruiting
- Sponsor
- GeneQuantum Healthcare
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of GQ1001 in HER2-positive solid tumor (HER2+), breast cancer, biliary tract cancer (BTC) and 3 more (2 arms), sponsored by GeneQuantum Healthcare. Primary endpoints: Dose Limiting Toxicities and Maximum Tolerated Dose or Dose Recommended for Dose Expansion at Cycle 1. Started Jul 2020; status: recruiting.
02
Drugs
GQ1001
03
Conditions
HER2-positive solid tumor (HER2+)breast cancerbiliary tract cancer (BTC)salivary gland carcinoma (SGC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04450732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450732.